Meningococcal vaccine in travelers

Current Opinion in Infectious Diseases

Volumn 20, Issue 5, 2007, Pages 454-460

  Wilder Smith, Annelies ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Conjugate vaccines; Hajj pilgrimage; Meningococcal disease; Meningococcal vaccines; Travel; W135 meningococcal disease

Indexed keywords

MENINGOCOCCUS VACCINE; POLYSACCHARIDE;

AFRICA; AUSTRALIA; BACTERIAL STRAIN; BLOOD GROUP TYPING; HUMAN; INDUSTRIALIZATION; MENINGITIS; MENINGOCOCCOSIS; NEW ZEALAND; NORTH AMERICA; REVIEW; SAUDI ARABIA;

AFRICA; AGE FACTORS; ASIA; DISEASE OUTBREAKS; HUMANS; IMMUNIZATION PROGRAMS; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; MIDDLE EAST; NEISSERIA MENINGITIDIS; SEROTYPING; TRAVEL; VACCINES, CONJUGATE;

EID: 34548436899     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3282a64700     Document Type: Review

References (30)

1. Wilder-Smith A, Memish Z. Meningococcal disease and travel. Int J Antimicrob Agents 2003; 21:102-106.
2. Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Engl J Med 2001; 344:1378-1388.
3. Pollard AJ. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J 2004; 23 (12 Suppl):S274-S279.
4. Thornton V, Lennon D, Rasanathan K, et al. Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control. Vaccine 2006; 24:1395-1400. A four-fold rise in serum bactericidal antibodies against the vaccine strain 4-6 weeks after the third vaccination was achieved in 100% of New Zealand candidate vaccine 25 μg participants and in 87% of 50 μg participants. The safety and immunogenicity profile observed in this study of healthy adults enabled studies in children to be initiated using 25 μg dosage.
5. Antignac A, Ducos-Galand M, Guiyoule A, et al. Neisseria meningitidis strains isolated from invasive infections in France (1999-2002): phenotypes and antibiotic susceptibility patterns. Clin Infect Dis 2003; 37:912-920.
6. The risk of epidemic meningitis in Africa: a cause for concern. Wkly Epidemiol Rec 2007; 82:77-88.
7. Traore Y, Njanpop-Lafourcade BM, Adjogble KL, et al. The rise and fall of epidemic Neisseria meningitidis serogroup W135 meningitis in Burkina Faso, 2002-2005. Clin Infect Dis 2006; 43:817-822. This shows the epidemiological trend of serogroup W135 meningococcal disease in Burkina Faso between 2002 and 2005.
8. Djibo S, Nicolas P, Alonso JM, et al. Outbreaks of serogroup X meningococcal meningitis in Niger 1995-2000. Trop Med Int Health 2003; 8:1118-1123.
9. Achtman M. Clonal spread of serogroup A meningococci: a paradigm for the analysis of microevolution in bacteria. Mol Microbiol 1994; 11:15-22.
10. Moore PS, Reeves MW, Schwartz B, et al. Intercontinental spread of an epidemic group A Neisseria meningitidis strain. Lancet 1989; 2:260-263.
11. Cochi SL, Markowitz LE, Joshi DD, et al. Control of epidemic group A meningococcal meningitis in Nepal. Int J Epidemiol 1987; 16:91-97.
12. Wilder-Smith A, Goh KT, Barkham T, Paton NI. Hajj-associated outbreak strain of Neisseria meningitidis serogroup W135: estimates of the attack rate in a defined population and the risk of invasive disease developing in carriers. Clin Infect Dis 2003; 36:679-683.
13. Wilder-Smith A, Barkham TM, Chew SK, Paton NI. Absence of Neisseria meningitidis W-135 electrophoretic Type 37 during the Hajj, 2002. Emerg Infect Dis 2003; 9:734-737.
14. Granoff DM, Gupta RK, Belshe RB, Anderson EL. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis 1998; 178:870-874.
15. Girard MP, Preziosi MP, Aguado MT, Kieny MP. A review of vaccine research and development: meningococcal disease. Vaccine 2006; 24:4692-4700.
16. Trotter CL, Chandra M, Cano R, et al. A surveillance network for meningococcal disease in Europe. FEMS Microbiol Rev 2007; 31:27-36. This is a good summary of the recent epidemiology of meningococcal disease in Europe.
17. Schmitt HJ, Maechler G, Habermehl P, et al. Immunogenicity, reactogenicity, and immune memory after primary vaccination with a novel Haemophilus influenzae-Neisseria meningitidis serogroup C conjugate vaccine. Clin Vaccine Immunol 2007; 14:426-434. A novel combined haemophilus B-MenC conjugate vaccine was shown to induce responses to serogroup C and haemophilus B comparable to those induced by licensed monovalent vaccines.
18. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2005; 54:1-21.
19. Pichichero M, Papa T, Blatter M, et al. Immune memory in children previously vaccinated with an experimental quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine. Pediatr Infect Dis J 2006; 25:995-1000. Persistence of bactericidal antibody was seen for 23-36 months after a primary dose of quadrivalent meningococcal conjugate vaccine in young children. Booster response was evident after a challenge with reduced-dose polysaccharide vaccine.
20. Pichichero M, Casey J, Blatter M, et al. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children. Pediatr Infect Dis J 2005; 24:57-62.
21. Update: Guillain-Barre syndrome among recipients of Menactra meningococcal conjugate vaccine: United States, June 2005-September 2006. MMWR Morb Mortal Wkly Rep 2006; 55:1120-1124 This summarizes post-licensure cases of Guillain-Barré syndrome after receiving quadrivalent meningococcal conjugate vaccine.
22. Holst J, Feiring B, Naess LM, et al. The concept of 'tailor-made', protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine 2005; 23:2202-2205.
23. Pollard AJ, Shlim DR. Epidemic meningococcal disease and travel. J Travel Med 2002; 9:29-33.
24. Koch S, Steffen R. Meningococcal disease in travelers: vaccination recommendations. J Travel Med 1994; 1:4-7.
25. Wilder-Smith A, Tai Goh K. W-135 meningococcal disease in a traveler: a case report. J Travel Med 2003; 10:59-60.
26. Riley LK. Bacterial meningitis exposure during an international flight: lessons for communicable pathogens. Aviat Space Environ Med 2006; 77:758-760.
27. O'Connor BA, Chant KG, Binotto E, et al. Meningococcal disease: probable transmission during an international flight. Commun Dis Intell 2005; 29:312-314.
28. Prevention CfDCa. Change in recommendation for meningococcal vaccine for travelers. MMWR Morb Mortal Wkly Rep 1999; 48:104.
29. Broker M. Vaccination against meningococal disease: which vaccine to use? J Travel Med 2002; 9:168.
30. El Bashir H, Heath PT, Papa T, et al. Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine. Vaccine 2006; 24:2544-2549. A randomized, modified, double-blind trial was conducted in children 2 to <5 years of age to evaluate immunogenicity and reactogenicity of a meningococcal (serogroups A, C, Y, W135) diphtheria toxoid conjugate vaccine (MCV-4) in healthy children previously vaccinated with a monovalent meningococcal C conjugate vaccine. No differences between the two groups were found.